Back to Search
Start Over
Correlation between bradykinin concentration and blood pressure during Rheocarna therapy: A single-center case series.
- Source :
-
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy [Ther Apher Dial] 2024 Jun; Vol. 28 (3), pp. 453-459. Date of Electronic Publication: 2024 Jan 03. - Publication Year :
- 2024
-
Abstract
- Introduction: A novel LDL (low-density lipoprotein) apheresis therapeutic option, Rheocarna, has garnered attention as an alternative therapy for chronic limb-threating ischemia (CLTI). Bradykinin-mediated vasodilation is involved in the effects of LDL apheresis and a decrease in blood pressure (BP), but the changes in bradykinin concentration during Rheocarna therapy are unknown.<br />Methods: The study involved patients with CLTI treated with Rheocarna at our hospital, from April 2022 to August 2023.<br />Results: After Rheocarna therapy, skin ulcers improved in 80% of the patients. Circuit coagulation was observed in two patients with high fibrinogen levels. A decrease in BP was observed at approximately the same time when the bradykinin concentration peaked. The peak bradykinin concentration in a patient undergoing hemodialysis at the same time was considerably lower than that in the other patients.<br />Conclusion: This is the first report on the changes in bradykinin concentration under Rheocarna therapy.<br /> (© 2024 International Society for Apheresis and Japanese Society for Apheresis.)
Details
- Language :
- English
- ISSN :
- 1744-9987
- Volume :
- 28
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 38173128
- Full Text :
- https://doi.org/10.1111/1744-9987.14105